Sonire Therapeutics, a U.S.-based clinical-stage medical device company, today announced the initiation of its first U.S. clinical trial, SUNRISE-II, evaluating its proprietary High-Intensity Focused ...

Sonire Therapeutics announced today that it initiated its first U.S. clinical trial, SUNRISE-II, evaluating its pancreatic ...

Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed to ablate pancreatic tumors, after ...

Sonire’s first U.S. study of ultrasound-guided, anesthesia-free HIFU ablation therapy has been launched for patients with ...

Focal One i expands HIFUsion ® patient-specific imaging compatibility to include PSMA PET, ExactVu™ Micro-Ultrasound, along with AI-driven and intelligent algorithms including Unfold AI™ and OnQ™ ...

CHARLOTTE, NC / ACCESSWIRE / April 16, 2024 / HIFU Prostate Services, LLC (HPS), the leading provider of non-invasive prostate cancer treatments, using High Intensity Focused Ultrasound (HIFU), is ...

The Fred Hutchinson Cancer Center recently added irreversible electroporation (IRE) to its slate of focal therapy offerings and is the only cancer center in the region to offer IRE, high-intensity ...

Appointment signals next phase of expansion for HIFU-based prostate care as demand grows for non-invasive, ...

One of the most common concerns about treating prostate cancer is preserving sexual function and urinary control. For some prostate cancers, newer treatments offering an alternative to radiation and ...

Record full-year 2024 HIFU revenue of USD 25.7 million, an increase of 15.3% over full-year 2023 Record Q4 2024 HIFU revenue of USD 9.3 million, an increase of 15.0% over Q4 2023 U.S. Focal One HIFU ...